For example, patients with decompensated cirrhosis indicated for vasoconstrictors and/or albumin treatment who may not respond (Cavallin et al., 2015; Wang et al., 2018; Moore et al., 2020) or those likely to develop respiratory failure (Wong et al., 2021) or other side effects (Martín–Llahí, 2008; Neri et al., 2008; Sanyal et al., 2008; Gluud et al., 2010). Here, ALB is linked to respiratory failure.